Your new post is loading...
Amgen, Inc. (NASDAQ:AMGN) has filed a Biologics License Application with the FDA for a new class of cholesterol-fighting drugs. It is competing with Sanofi SA (ADR) (NYSE:SNY) to be the first to tap into the $10 billion market.
Via Krishan Maggon
|
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies |
Scoop.it!
Via Krishan Maggon
Gilbert C FAURE's insight:
immunological molecules everywhere
Evolocumab vs Alirocumab market war to dominate the new mabs superstatins market worth $10 billion.
These mabs discussed in previous scoops.